Skip to Main Content

Paper Details

Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study.
Am J Hematol
0
2023
Author NameAffiliation
Courtney D DiNardoMD Anderson Cancer Center, University of Texas
Daniel A PollyeaUniversity of Colorado
Richard M StoneDana-Farber Cancer Institute
  • 1 - 3

Datasets

Release 1.2